Navigation Links
Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
Date:9/26/2007

COLORADO SPRINGS, Colo., Sept. 26 /PRNewswire-FirstCall/ -- Spectranetics Corporation (Nasdaq: SPNC) today announced it has enrolled the first patient in the PATENT trial utilizing the Company's TURBO elite(TM) laser catheters in combination with the recently FDA cleared TURBO-Booster(TM).

The PATENT trial is a prospective registry of 100 patients at up to 10 sites in Germany. The trial will assess patency as measured by duplex ultrasound at various intervals up to 12 months following the procedure. It will also assess safety as measured by adverse events up to 12 months following the procedure. In the initial procedure performed at the Leipzig Heart Center, four focal lesions were treated successfully with the TURBO-Booster and TURBO elite 2.0mm catheter in a 20cm long stented superficial femoral artery.

"The initial result from this Spectranetics device looks very promising, as the new features allow for ablation of more tissue in larger vessels," said Andrej Schmidt, M.D., of the University of Leipzig-Heart Center. "Instent restenosis in a superficial femoral artery represents one of the most challenging procedures in our practice. The current standard of care, such as repeat balloon angioplasty, does not have good results as these lesions tend to reoccur. We are very excited with the start of this study in Germany, and we look forward to examining the mid- and long-term results of this new therapy."

John G. Schulte, Spectranetics' President and Chief Executive Officer, commented, "We are very pleased to have begun this trial at one of Europe's most prestigious medical centers. We believe that instent restenosis in the superficial femoral artery may represent 25% to 35% of all above-the-knee procedures, and there is currently not a good solution for this challenging lesion subset."

About Spectranetics

Founded in 1984, Spectranetics manufactures and sells the only excimer laser approved in the United States, Europe and Japan for use in minimally invasive cardiovascular procedures. This technology treats complex cardiovascular conditions by photo-ablating multiple lesion types into tiny particles that are easily absorbed into the blood stream. The Company's disposable catheters use high-energy "cool" ultraviolet light to vaporize arterial blockages in the legs and heart, as well as scar tissue encapsulating pacing and defibrillation leads. For more information visit http://www.spectranetics.com.

Safe Harbor Statement

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties may include increasing price and product competition, increased pressure on expense levels resulting from expanded marketing and clinical activities, uncertain success of the Company's strategic direction, dependence on new product development, intellectual property claims of third parties, availability of inventory from suppliers, the receipt of FDA approval to market new products or applications and the timeliness of any approvals, the potential size of market opportunities associated with new products, market acceptance of new products or applications, product defects, unexpected delays or costs associated with the Company's relocation and consolidation of its headquarters and manufacturing operations, price volatility due to the initiation or cessation of coverage, or changes in ratings, by securities analysts. For a further list and description of such risks and uncertainties that could cause the actual results, performance or achievements of the Company to be materially different from any anticipated results, performance or achievements, please see the Company's previously filed SEC reports. Spectranetics disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether as a result of new information, future events or otherwise.

COMPANY CONTACT: INVESTOR RELATIONS CONTACTS

Spectranetics Corporation Lippert/Heilshorn & Associates, Inc.

Guy Childs, Chief Financial Officer Bruce Voss/Don Markley

(719) 633-8333 (310) 691-7100

http://www.spectranetics.com http://www.lhai.com

MEDIA RELATIONS CONTACT:

Schwartz Communications, Inc.

Stacey Holifield

(781) 684-0770

spectranetics@schwartz-pr.com


'/>"/>
SOURCE Spectranetics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
7. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
10. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)...  As part of a major growth and expansion initiative, ... Lori Chmura as President of Dune Inc., its ... Chmura,s extensive experience in the medical device space will play ... --> --> In ... sales, marketing and operational functions in the U.S. She is ...
(Date:2/8/2016)... , Feb. 8, 2016  The University of ... announced today that, as part of the development ... of the first hospitals in the U.S. to start ... Muraszko , M.D., U-M,s chair of neurosurgery. ... neurosurgery. --> The BrightMatter technology from ...
(Date:2/8/2016)...  Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) today announced ... December 31, 2015, the Company achieved revenue of $8,195,839, a ... quarter in fiscal 2015. --> ... year 2016 was $2,068,635, or $.03 per share, up 265% ... in the Q2 of fiscal year 2015. Gross margin for ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... The Bell Agency, a full ... beneficiary of their ongoing community enrichment program. The current campaign fundraises for Angels ... are now being accepted at: http://www.angelsanddoves.com/donate.html . , Angels & Doves was ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... executive networking and relationship-marketing firm, announced today that nominations will be accepted ... Executive® (ISE®) West Awards. , Awards include the Information Security Executive® ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... a wide variety of organizations. DocuSyst provides a cloud hosted environment for ... Some installations include integration with various 3rd party applications using the FileHold web ...
(Date:2/8/2016)... MD (PRWEB) , ... February 08, 2016 , ... ... is excited to share this important news! AHCC and the Home Health and ... Coding Clinic, CMS' designee for official ICD coding guidance and clarifications, to address ...
(Date:2/8/2016)... ... February 08, 2016 , ... Guruji Mahendra Kumar Trivedi is ... 11th, 2016 in honor of his birthday on February 10th. During this time, ... Trivedi is known by over 250,000 people from over 40 different countries as an ...
Breaking Medicine News(10 mins):